New hope for hard-to-treat leukemia: old drug shows promise in combo therapy

This early-stage study tests whether adding mitoxantrone to the usual venetoclax+azacitidine regimen can help adults with acute myeloid leukemia (AML) whose cancer did not respond or came back after initial treatment. About 30 participants will receive different doses to find the safest and most effective combination. The goal is to control the disease, not cure it, as ongoing management is expected.